Search Results - "Fresan Restituto, D"

Salvage therapy for patients who do not respond to the first anti-CGRP monoclonal antibody: a new chance for patients with migraine? by Fresan Restituto, D., Lacalle Fabo, E., Martin Bujanda, M.

Get full text

4CPS-360 Risk of malnutrition in patients with COVID-19 disease who receive oral nutritional supplements by Calvo Arbeloa, M, Pinilla Lebrero, G, Fresan Restituto, D, Ortega Belio, I, Rodriguez Esquiroz, A, Tejada Marin, D, Ulacia Epelde, L, Illodo Becerra, JA, Elizondo Armendariz, J, Sarobe Carricas, M

“…Background and importanceThe European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend the optimisation of the nutritional status of…”
Get full text

4CPS-114 Integration of a pharmacist into a geriatric department by Tejada Marín, D, Rodriguez Esquiroz, A, Fresán Restituto, D, San Miguel Elcano, R, Cedeño Veloz, A, Roncal Belzunce, V, Martinez Velilla, N, Sarobe Carricas, M

“…Background and importanceElderly chronic patients are usually pluripathological and polymedicated, which makes them vulnerable and complex to deal with. The…”
Get full text

5PSQ-149 Durvalumab for the treatment of non-small cell lung cancer: real-world experience by Ulacia Epelde, L, Ortega Belio, I, Larrea Goñi, N, Egüés Lugea, A, de la Riva Bohigas, R, Aldave Cobos, P, Irigoyen Rodriguez, I, Fresán Restituto, D, Lamas Pillo, A, Rodríguez Esquíroz, A, Tejada Marín, D

“…Background and importanceDurvalumab is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours…”
Get full text

4CPS-142 Effectiveness and safety of anti-IL-5 biologic agents in severe eosinophilic asthma by Calvo Arbeloa, M, Pinilla Lebrero, G, Lacalle Fabo, E, Polo García, J, Ulacia Epelde, L, Illodo Becerra, J, Fresán Restituto, D, Aldave Cobos, P, Elizondo Armendáriz, J, Sarobe Carricas, M

“…Background and importanceSevere uncontrolled asthma is characterised by poor control despite treatment with inhaled glucocorticoids (IGC) and beta2 adrenergic…”
Get full text

Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one by Fresán-Restituto, D, Lacalle-Fabo, E, Martín-Bujanda, M, Sarobe-Carricas, M T

“…TITLEEfecto beneficioso del cambio a un segundo anticuerpo monoclonal anti-CGRP en pacientes con migraña no respondedores a un primero…”
Get full text